Gilead Sciences, Inc. [GILD] stock is trading at $89.00, up 0.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GILD shares have gain 2.63% over the last week, with a monthly amount glided 7.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on October 21, 2024, when Leerink Partners upgraded its rating to a Outperform and also boosted its price target to $96 from $74. Previously, Bernstein started tracking the stock with Outperform rating on October 17, 2024, and set its price target to $105. On October 07, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $100 on the stock. Raymond James upgraded its rating to a Outperform but stick to its price target of $93 on July 08, 2024. Maxim Group reiterated its recommendation of a Buy and reduced its price target to $85 on May 01, 2024. HSBC Securities upgraded its rating to Hold for this stock on April 24, 2024, but kept the price target unchanged to $69. In a note dated February 22, 2024, Truist downgraded an Hold rating on this stock and revised its target price from $91 to $82.
Gilead Sciences, Inc. [GILD] stock has fluctuated between $62.07 and $89.21 over the past year. Currently, Wall Street analysts expect the stock to reach $81.32 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $89.00 at the most recent close of the market. An investor can expect a potential drop of -8.63% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc. [NASDAQ:GILD] reported sales of 27.78B for the trailing twelve months, which represents a growth of 5.46%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.39 points at the first support level, and at 87.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 89.68, and for the 2nd resistance point, it is at 90.35.
Ratios To Look Out For
For context, Gilead Sciences, Inc.’s Current Ratio is 1.14. Also, the Quick Ratio is 0.95, while the Cash Ratio stands at 0.26. Considering the valuation of this stock, the price to sales ratio is 3.99, the price to book ratio is 6.07 and price to earnings (TTM) ratio is 108.78.
Transactions by insiders
Recent insider trading involved Parsey Merdad, Chief Medical Officer, that happened on Oct 01 ’24 when 2000.0 shares were sold. Officer, MERDAD V PARSEY completed a deal on Oct 01 ’24 to buy 2000.0 shares. Meanwhile, Chief Medical Officer Parsey Merdad sold 21246.0 shares on Sep 12 ’24.
